Overall survival results for durvalumab and savolitinib in metastatic papillary renal cancer.

• DOI: 10.1200/jco.2020.38.6_suppl.619
• Publication Date: 2020-02-19T16:59:57Z
• Authors: Cristina Suarez R...; James M. G. Larkin; Poulam Patel; Begona Pérez Vald...; Alejo Rodriguez-Vida; Hilary Glen; Fiona Thistlethwaite; Christy Ralph; Gopalakrishnan Sr...; Maria Jose José M...; Abigail Carter; Charlotte Tyson; Aaron Prendergast; Kelly Mousa; Thomas Powles
• Keywords: Durvalumab; Tolerability; Urothelial cancer

619 Background: There is a strong rationale for investigating MET and PD-L1 inhibition in metastatic papillary renal cancer (PRC). We previously reported response rates (RR) progression free survival (PFS) savolitinib (MET inhibitor) durvalumab (PD-L1 together. Here we report overall (OS) data available 12 months after the last patient was enrolled. Methods: This single arm phase I/II trial explores (1500mg Q4W) (600mg OD) together PRC, with 4wk run in. Treatment naïve or treated patients PRC were included. Confirmed RR (RECIST v1.1), PFS, tolerability (CTCAE v4.03) analysed. biomarkers explored (NCT02819596). Results: 42 enrolled 41 receiving at least one dose of study treatment. Safety efficacy analyses performed on these patients. The median follow up 14.3 months. IMDC good, intermediate poor risk disease occurred 29%, 63%, 7% respectively. Overall confirmed 27% while PFS 4.9 (95% CI: 2.5 – 12.0 months). Median OS 12.3 5.8 21.3 untreated cohort (N=27) 33% 4.7 not reached (NR) months) related Grade 3/4 toxicity 34% No new safety signals seen. expression associated higher (25% 40% respectively) longer OS. Conclusions: combination has clinical activity outcomes enhanced biomarker positive cancers. Clinical information: NCT02819596.